This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Hypoproconvertinemia저프로콘버틴혈증

Contents and key points
ItemDetails
A. Classification codesICD-10: D68.2 | Special Copayment Reduction: V009 (rare disease)
B. SynonymsStable factor deficiency, Factor VII deficiency, FVII deficiency
C. Adult onsetHigh — incidental detection before surgery due to isolated PT prolongation is common; mild cases (FVII:C >10%) may remain asymptomatic into adulthood; severe cases may have spontaneous bleeding from childhood.
1. HistoryIndependent descriptions by Alexander and Owren in 1951. Origin of the name proconvertin. The nickname 'stable factor'. Connection to Owren's coagulation factor nomenclature.
2. CausesF7 gene (13q34) variants; autosomal recessive; vitamin K-dependent; various missense, nonsense, and splicing variants; population-specific founder variants exist.
3. GeneticsF7 gene 13q34, 9 exons; vitamin K-dependent protein; Gla domain; half-life 3–6 hours (shortest among coagulation factors).
4. EpidemiologyAbout 1 in 500,000 (congenital severe deficiency); one of the most common rare coagulation factor deficiencies; high frequency of founder variants in Iran and Israel.
5. PathophysiologyFVII → FVIIa forms a complex with TF (TF-FVIIa) → activation of FX and FIX → initiation of the extrinsic pathway; key role in the initiation phase in the cell-based model of hemostasis.
6. SymptomsFVII:C disproportionate to bleeding severity (similar to FXI deficiency); intracranial hemorrhage, muscle hematomas, and hemarthrosis in severe cases; bleeding after surgery or delivery in mild cases; menorrhagia.
7. SignsIsolated PT prolongation (normal APTT); reduced FVII:C; differentiation from other causes of PT prolongation needed (vitamin K deficiency, warfarin use, liver disease).
8. ScreeningIncidental detection of isolated PT prolongation before surgery; confirmation of response to vitamin K administration; FVII:C single-factor assay; family history testing.
9. DiagnosisPT prolongation → vitamin K differentiation → FVII:C single-factor assay → mixing test → F7 gene analysis; severity classification (severe <1%, moderate 1–10%, mild >10%).
10. TreatmentRecombinant FVIIa (rFVIIa, NovoSeven®); plasma-derived FVII concentrate; FFP; vitamin K (some cases); frequent dosing needed because of the 3–6 hour half-life.
11. PrognosisHigh risk of intracranial hemorrhage in severe deficiency; preventable with appropriate treatment; prognosis difficult to predict because of the discrepancy between FVII:C and clinical bleeding severity.
12. PreventionProphylaxis in severe deficiency; preoperative FVII replacement planning; supplementation after differentiation of vitamin K deficiency; genetic counseling.
13. ReferencesAlexander B et al. 1951 first description of FVII and 11 or more other key references.

1. History

Naming of 'proconvertin': from precursor factor to activated factor

The name hypoproconvertinemia derives from proconvertin, the historical name for coagulation factor VII (FVII). The name proconvertin reflected the functional concept that this factor exists in serum as an inactive precursor in the coagulation reaction (proconvertin = convertin before activation) and, when activated, becomes convertin, which activates other factors. In 1951, the Norwegian hematologist Paul Arnald Owren and the American Benjamin Alexander each independently described a new coagulation factor deficiency state and named the factor differently. Owren named it 'proconvertin', a new factor distinguished in the context of 'factor V deficiency', while Alexander et al. named it 'SPCA (serum prothrombin conversion accelerator)'. Later, the international nomenclature committee standardized the new factor as Factor VII at its 1954 Rome meeting, and proconvertin remained as a synonym.

The historical nickname 'stable factor'

Another historical name for FVII is stable factor. This name came from the property, observed in coagulation research in the 1940s–50s, that FVII activity remained far more stable than that of other factors (especially the hemophilia factors, i.e., FVIII and FV) when plasma or serum was stored cold or heated. Whereas FVIII (the hemophilia A factor, then also called 'labile factor') was rapidly inactivated by storage or temperature change, FVII activity was well preserved even when plasma was incubated at 37°C for several hours. This difference made it possible to design experiments to confirm the presence of FVII activity, and the name 'stable factor' arose from this experimental property. However, this name seems superficially to contradict the short half-life of FVII (3–6 hours) revealed by modern molecular research; it should be understood that in vitro storage stability and in vivo half-life are different concepts.

Owren's coagulation factor nomenclature and the place of FVII

The history of FVII is inseparable from the extensive coagulation research of the Norwegian hematologist Owren. Owren (Paul Arnald Owren, 1905–1990) not only first described coagulation factor V (FV) deficiency in 1947, naming it 'parahemophilia', but was also the first to propose a nomenclature assigning Roman numerals to coagulation factors. His coagulation factor classification (Factor I fibrinogen, II prothrombin, III thromboplastin, IV calcium, V proaccelerin/labile factor) became the basis on which the international nomenclature committee later established the worldwide unified Factor I–XIII nomenclature. Owren's separation of FVII as a distinct coagulation factor and naming it 'proconvertin' established FVII within the classification system he had proposed. In this context, 'hypoproconvertinemia', the historical name for FVII deficiency, is also a name that carries Owren's scholarly legacy.

Development of recombinant FVIIa (rFVIIa) and a new history

The most important turning point in the history of FVII deficiency treatment is the development of recombinant activated factor VII (rFVIIa, brand name NovoSeven®). rFVIIa, first reported in 1988 by Ulla Hedner (Sweden) and the Novo Nordisk research team, was originally developed for bypassing hemostasis in hemophilia A and B patients with inhibitors, but it has also been approved by the FDA and EMA as a definitive treatment for FVII deficiency. Pharmacokinetically, unlike endogenous FVII, rFVIIa is already in the activated form (FVIIa), so after administration it can immediately bind TF and initiate the coagulation pathway. Its half-life is short at about 2.7 hours (intravenous), requiring frequent dosing, but it has the advantages of no risk of viral transmission and being a pure single-factor product. The development of rFVIIa and its application to FVII deficiency treatment is an important milestone in the history of treatment of rare coagulation factor deficiencies.


2. Causes

F7 gene variants

Hypoproconvertinemia (FVII deficiency) is caused by pathogenic variants in the F7 gene located on the long arm of chromosome 13 at 13q34. The F7 gene is about 13 kb long, consists of 9 exons, and encodes the mature FVII protein (406 amino acids, molecular weight about 50 kDa). The mode of inheritance is autosomal recessive, and complete deficiency manifests only when both alleles carry variants (homozygous or compound heterozygous). In heterozygous carriers, FVII:C is reduced to about 40–65% of normal, and PT may be mildly prolonged, but most have no clinical bleeding. To date, more than 200 pathogenic variants have been reported in the F7 gene, of various types including missense variants (most common), nonsense variants, splicing variants, and insertions/deletions. The F7 gene lies adjacent to the F10 (factor X) gene on chromosome 13q34, about 2.8 kb apart, and gene recombination or combined variants between these two genes have rarely been reported.

Vitamin K dependence and differentiation from acquired deficiency

FVII is one of the four vitamin K-dependent coagulation factors (FII, FVII, FIX, FX); during synthesis in the liver, the glutamic acid (Glu) residues of the Gla domain must be converted to gamma-carboxyglutamic acid (Gla) by the vitamin K-dependent gamma-carboxylation (γ-carboxylation) enzyme for Ca²⁺ binding and phospholipid binding to be possible. FVII can be functionally activated only when this Gla domain is fully carboxylated. Therefore, in vitamin K deficiency (nutritional deficiency, malabsorption, liver disease) or with use of vitamin K antagonists (warfarin, acenocoumarol), FVII:C decreases and PT is prolonged. This is the most important acquired condition to differentiate from congenital FVII deficiency. In congenital deficiency, FVII:C is not corrected after vitamin K administration, whereas in vitamin K deficiency, FVII:C normalizes within 24–48 hours after vitamin K administration. In liver disease, not only FVII but also other liver-synthesized factors (FII, FV, FX, FI, etc.) are reduced at the same time, so it is important to distinguish isolated FVII deficiency from liver disease with multiple factor reductions.

Founder variants in Iran and Israel

In FVII deficiency, founder effects have been confirmed in certain ethnic groups. In the Iranian population, the F7 gene IVS7+1G>A splicing variant has been reported at relatively high frequency; this variant destroys the donor splice site of intron 7, producing abnormal mRNA and greatly reducing production of functional FVII protein. A specific F7 variant has also been reported at high frequency in the Iraqi Jewish population of Israel. Clustering of F7 variants in certain regions has also been reported in Italy. Overall, FVII deficiency is not concentrated in particular ethnic groups and is distributed worldwide, but the frequency of homozygous complete deficiency is relatively high in populations where consanguineous marriage is common. In Korea, there are no systematic studies of F7 founder variants, but with the spread of NGS-based panel testing, the domestic F7 variant spectrum is gradually being revealed.

Special conditions related to FVII: combined FVII/FX deficiency and abnormalities of vitamin K metabolism

Because the F10 gene is located very close to the F7 gene, chromosomal rearrangements affecting both genes rarely occur and can cause congenital combined FVII/FX deficiency. In this rare condition, both PT and APTT are prolonged, and diagnosis requires measuring both FVII and FX single factors. In addition, in congenital disorders of vitamin K metabolism (e.g., VKCFD, vitamin K-dependent coagulation factor deficiency), all vitamin K-dependent coagulation factors (FII, FVII, FIX, FX) may be congenitally reduced, which must be clearly distinguished from isolated FVII deficiency. VKCFD is caused by variants in the GGCX (gamma-glutamyl carboxylase) or VKORC1 (vitamin K epoxide reductase complex subunit 1) genes and is partially corrected by high-dose vitamin K supplementation.


3. Genetics

F7 gene structure and FVII protein domains

The F7 gene is located on the long arm of chromosome 13 at 13q34; its official HGNC symbol is F7 and its Entrez Gene ID is 2155. The total length of the gene is about 13 kb, and it consists of 9 exons. The mature FVII protein consists of 406 amino acids (molecular weight about 50 kDa) and is structurally divided into the following four domains: (1) Gla domain (N-terminal, 38 amino acids): contains 10 Gla residues and is essential for Ca²⁺ binding and phospholipid binding (cell membrane phospholipids at sites of TF exposure). This domain is the target of vitamin K-dependent gamma-carboxylation. (2) EGF1 domain: an epidermal growth factor (EGF)-like domain involved in protein stability and interactions with FIXa and TF. (3) EGF2 domain: another EGF-like domain that contributes to binding affinity for TF. (4) Serine protease domain (C-terminal): contains the catalytic triad (His193-Asp242-Ser344) and is responsible for cleaving (activating) FX and FIX. FVII is converted to the two-chain form (light chain 16 kDa + heavy chain 34 kDa), FVIIa (active form), by cleavage at Arg152-Ile153.

Half-life of FVII: the shortest of all coagulation factors

FVII has a plasma half-life of about 3–6 hours, the shortest of the known coagulation factors. This extremely short half-life has important clinical implications for the treatment of FVII deficiency. First, because the plasma half-life of FVII given therapeutically (recombinant rFVIIa or plasma-derived FVII concentrate) is short, frequent redosing (every 2–6 hours) is needed around surgery or in the treatment of acute bleeding. Second, in short-term fasting, acute liver dysfunction, and vitamin K deficiency, FVII tends to decrease markedly before other factors, so FVII is used as a sensitive indicator of hepatic synthetic capacity. Third, differences in the half-lives of plasma coagulation factors are clinically important in PT measurement of the extrinsic pathway; early in warfarin therapy, FVII is the first of the vitamin K-dependent factors to fall, so PT is rapidly prolonged. This is why the INR rises quickly early in warfarin therapy.

Autosomal recessive inheritance and heterozygous carriers

Because FVII deficiency is autosomal recessive, males and females are equally affected. Heterozygous carriers (FVII:C about 40–65%) usually have no clinical bleeding, but there are reports that bleeding may increase with major surgery or childbirth. PT in heterozygous carriers may be slightly prolonged or close to the upper limit of the normal range, and when mild PT prolongation is found on preoperative testing, the possibility of heterozygous FVII deficiency should be considered. When both parents are heterozygous carriers, the probability that a child has complete deficiency (homozygous or compound heterozygous) is 25%. Recommending FVII:C testing to the parents and siblings of FVII deficiency patients helps with family diagnosis, and a preventive plan can be established before surgery based on this information.

F7 gene polymorphisms and studies of thrombotic and cardiovascular risk

In addition to disease-causing pathogenic variants, the F7 gene has polymorphisms that affect plasma FVII levels or activity. The best studied is the Gln353Arg (R353Q, rs6046) polymorphism in exon 6; carriers of the Arg allele (FVII Arg353 in some literature) are known to have plasma FVII:C about 20–25% lower. Early studies suggested this polymorphism might have a protective effect against myocardial infarction, but subsequent large studies found this association to be inconsistent. A polymorphism in the promoter region (D/I polymorphism, -323 insertion/deletion) has also been reported to affect FVII:C levels. In clinical interpretation, it should be carefully assessed how these polymorphisms are distinguished from pathogenic variants, and whether they cause FVII:C reduction to heterozygous carrier levels or lower-end variation within the normal range.


4. General epidemiology

Prevalence: the most common rare coagulation factor deficiency

The prevalence of congenital FVII deficiency (severe, FVII:C <1%) is estimated at about 1 in 500,000, making it one of the most common rare coagulation factor deficiencies (excluding hemophilia A and B) in World Federation of Hemophilia (WFH) data. Including moderate deficiency (FVII:C 1–10%), the prevalence is higher. Considering mild deficiency (FVII:C 10–50%) down to the heterozygous carrier level, it is not uncommon in the general population, and in such cases incidental detection before surgery is the main clinical route. In the WFH 2023 annual survey, the number of registered FVII deficiency patients worldwide was reported as about 3,000–4,000, but this is an underestimate counted mainly from diagnosed severe patients. The male-to-female ratio is 1:1 (autosomal recessive).

Relationship between clinical severity classification and prevalence

The clinical severity of FVII deficiency is classified according to plasma FVII:C activity level, and the prevalence and clinical significance of each category differ. In severe (FVII:C <1 IU/dL) deficiency, spontaneous bleeding (intracranial hemorrhage, muscle hematomas, hemarthrosis, gastrointestinal bleeding) can occur, and diagnosis is often made in infancy or childhood. In moderate (FVII:C 1–10 IU/dL) deficiency, excessive bleeding occurs with hemostatic stress such as surgery, trauma, or tooth extraction, but spontaneous bleeding is rare. In mild (FVII:C >10 IU/dL) deficiency, bleeding appears only with major surgery or severe trauma, or the patient remains asymptomatic and is detected by PT prolongation before surgery. However, the difficulty in clinical management is that even in FVII deficiency, there is no complete proportional relationship between FVII:C level and clinical bleeding severity. Bleeding phenotypes may differ even among patients with the same FVII:C level.

FVII deficiency and thrombosis: epidemiology of a paradoxical relationship

Theoretically, FVII deficiency would be expected to cause a bleeding tendency through impaired initiation of the extrinsic pathway, but in practice thrombosis has been reported in some FVII deficiency patients. Cases of venous thromboembolism and arterial thrombosis in FVII deficiency patients have been reported in the literature, and a hypothesis has also been proposed that in some F7 gene variants a nonfunctional FVII protein is synthesized (CRM+ variants), which interferes with excessive TF-FVIIa complex formation and may instead act toward loss of part of the inhibitory regulatory function of the TF pathway. However, the epidemiological significance of this phenomenon has not yet been established, and studies of the association between FVII deficiency and thrombosis are ongoing. Clinically, when a thrombotic event occurs in an FVII deficiency patient, other thrombophilic factors must be evaluated.

Current status in Korea and the need for registration

In Korea, FVII deficiency (hypoproconvertinemia) has far fewer registered patients than hemophilia A and B, and the number of registered patients identified in data from the Korea Hemophilia Foundation or the Health Insurance Review & Assessment Service (HIRA) is estimated at a few dozen. Many patients found to have isolated PT prolongation before surgery are misdiagnosed as taking warfarin or having vitamin K deficiency, or remain undiagnosed, without FVII:C being measured, so the actual prevalence may be higher than identified. Systematic genetic analysis and clinical registry studies of FVII deficiency are needed in Korea, which would contribute to identifying the domestic F7 variant spectrum, preventing diagnostic delay, and securing insurance coverage for treatments.


5. Pathophysiology

FVII as the initiating factor of the extrinsic pathway

Coagulation factor VII (FVII) is the key factor initiating the extrinsic pathway (tissue factor pathway) of blood coagulation. When a blood vessel is injured, tissue factor (TF, factor III) expressed on subendothelial cells (fibroblasts, vascular smooth muscle cells, monocytes, etc.) is exposed to the bloodstream. This TF binds FVII circulating in plasma (or the small amount already activated, FVIIa) to form the TF-FVIIa complex. This complex has very potent enzymatic activity and activates FX and FIX simultaneously. It directly activates FX to FXa to generate an initial small amount of thrombin (prothrombinase complex → initial thrombin), and activates FIX to FIXa, contributing to the subsequent intrinsic tenase (FIXa-FVIIIa) complex. This initial thrombin triggers platelet activation, activation of FV, FVIII, and FXIII, and conversion of fibrinogen to fibrin, amplifying the hemostatic response.

Role of TF-FVIIa in the cell-based model of hemostasis

Whereas the traditional coagulation cascade model explains in vitro phenomena well, the cell-based model of hemostasis better explains how hemostasis occurs in vivo. In the cell-based model, hemostasis occurs in three phases: in the initiation phase, TF-FVIIa generates small amounts of FXa, FIXa, and thrombin on the surface of TF-expressing cells (mainly adventitial fibroblasts). In the amplification phase, this initial thrombin activates platelets and promotes activation of FV, FVIII, and FXI on the platelet surface. In the propagation phase, FIXa-FVIIIa (intrinsic tenase) and FXa-FVa (prothrombinase) on the activated platelet surface generate large amounts of thrombin, stabilizing the fibrin clot. In FVII deficiency, the initiation phase is impaired and initial thrombin generation is insufficient, so the amplification and propagation phases are also weakened in a cascade. However, one explanation for the disproportion between FVII:C and bleeding is that in some patients hemostasis can be maintained through compensation by the intrinsic pathway via FXI.

Mechanisms of the disproportion between FVII deficiency and bleeding severity

The disproportion between FVII:C and clinical bleeding severity in FVII deficiency is explained by several mechanisms. First, even at low FVII:C levels (e.g., 1–5 IU/dL), binding affinity for TF (the ability to form the TF-FVIIa complex) is not completely lost, so small amounts of TF-FVIIa can still trigger initial thrombin generation. Second, compensation by the intrinsic pathway via FXI may differ between individuals, so in individuals with high FXI levels the effect of FVII deficiency is partly offset. Third, in individuals with low concentrations of tissue factor pathway inhibitor (TFPI), inhibition of the TF-FVIIa complex is reduced, so even small amounts of TF-FVIIa can remain active longer. Fourth, differences in FVII distribution in the body (plasma vs. tissue storage pool) may affect actual hemostatic capacity. These combined mechanisms are why diverse bleeding phenotypes appear at the same FVII:C.

FVII and non-coagulation functions: cell signaling and non-hemostatic roles

FVII and TF are known to be involved in various cell signaling processes beyond coagulation. The TF-FVIIa complex activates PAR-2 (protease-activated receptor 2), transmitting signals that promote proliferation, migration, and angiogenesis of endothelial and tumor cells. TF is also essential for fetal vascular development, so TF gene-deleted mice show embryonic lethality. FVII-deficient mice are viable but show a bleeding tendency, confirming that TF and FVII play a more central role in maintaining hemostasis than in fetal development. Studies show that TF overexpression in cancer contributes to the progression and metastasis of malignant tumors, and the TF-FVII signaling pathway is being studied as an anticancer target. These non-coagulation roles leave open the possibility of indirect effects on the long-term prognosis or general health of FVII deficiency.


6. Symptoms

Diversity of bleeding symptoms and disproportion with FVII:C

The clinical bleeding pattern of FVII deficiency is very diverse, and bleeding tendency can differ greatly between patients even with the same FVII:C level. As a general tendency, however, spontaneous bleeding can occur in severe deficiency with FVII:C <1%, excessive bleeding mainly with hemostatic stress in moderate deficiency of 1–10%, and in mild deficiency of 10% or more bleeding appears only with major surgery or severe trauma, or the patient is asymptomatic. This classification is not absolute, and the phenotypic diversity even within the same variant makes FVII deficiency clinically complex. Notably, there are reported cases of patients with unmeasurable (very low) FVII:C who lived their whole lives without bleeding, while there are also cases of serious bleeding in patients with relatively high FVII:C of 10–20%.

Spontaneous bleeding in severe FVII deficiency

In severe FVII deficiency (FVII:C <1 IU/dL), the most important spontaneous bleeding manifestation is intracranial hemorrhage (ICH). The risk of intracranial hemorrhage in FVII deficiency is not as high as in FXIII deficiency (about 25–30% lifetime), but it is relatively high among all congenital coagulation factor deficiencies. There are reports that the intracranial hemorrhage risk of FVII deficiency is higher even than that of severe hemophilia A (FVIII deficiency) (about 2–5%). This is explained by the particularly important role of the extrinsic pathway in cerebral vascular hemostasis. Spontaneous joint bleeding (hemarthrosis) and muscle hematomas also occur in severe deficiency and, when recurrent, can cause chronic joint damage similar to hemophilia A and B. Gastrointestinal and urinary tract bleeding have also been reported.

Symptoms of moderate and mild FVII deficiency

In moderate deficiency (FVII:C 1–10 IU/dL), spontaneous bleeding is rare, and excessive bleeding occurs mainly in situations of hemostatic stress such as surgery, tooth extraction, trauma, and childbirth. Delayed postoperative bleeding, recurrent bleeding after tooth extraction, and bleeding after tonsillectomy are characteristic. In women, menorrhagia is prominent, and the risk of bleeding during pregnancy and delivery also increases. Mild deficiency (FVII:C >10 IU/dL) is most often asymptomatic and detected incidentally by PT prolongation before surgery. In this case, most surgeries can be performed safely without special treatment, but for surgery on vital organs (brain, spine, eyes, abdominal cavity, etc.) or surgery with expected major bleeding, prior consultation with a hematologist to decide on preventive measures is recommended.

Special features of neonatal and infantile presentation

Severe FVII deficiency may present in the neonatal period or infancy, and intracranial hemorrhage at this age has a particularly serious prognosis. FVII deficiency-related intracranial hemorrhage presenting in the neonatal period must be differentiated from hemorrhagic disease of the newborn (HDNB) due to vitamin K deficiency. Correction after vitamin K administration suggests vitamin K deficiency, and if not corrected, congenital FVII deficiency should be suspected. When a newborn has prolonged PT that is not corrected even with vitamin K administration, FVII:C should be measured immediately to determine whether congenital deficiency is present. In newborns of pregnant women with a family history of FVII deficiency, FVII:C is checked immediately after birth, and if deficiency is confirmed, immediate treatment and a long-term management plan are established.


7. Signs

Isolated PT prolongation: the characteristic test pattern of FVII deficiency

The most characteristic coagulation test finding of FVII deficiency (hypoproconvertinemia) is isolated prolongation of the prothrombin time (PT). Because PT measures the time for a fibrin clot to form after adding tissue thromboplastin (a mixture of TF and phospholipid), which initiates the extrinsic pathway (TF-FVIIa), and calcium to plasma, deficiency of FVII, which is involved only in the extrinsic pathway, selectively prolongs PT. APTT uses the intrinsic pathway (contact factors), so it is not affected by FVII deficiency and is normal. TT, platelet count, and bleeding time are also normal. This pattern—prolonged PT, normal APTT—occurs commonly in deficiencies of extrinsic or common pathway factors (including FX, FV, FII, FI), vitamin K deficiency, and warfarin use, so the cause must be identified with additional tests. The degree of PT prolongation is roughly inversely proportional to the FVII:C level, but the exact relationship differs with the type of test reagent.

Differentiating the causes of PT prolongation

When isolated PT prolongation is found, the main causes to differentiate are as follows. Warfarin use or vitamin K antagonists: the most common cause; checking the medication history comes first. During warfarin therapy, all vitamin K-dependent factors (FII, FVII, FIX, FX) are reduced, so PT prolongation is much more severe than in isolated FVII deficiency, and APTT is often prolonged as well. Vitamin K deficiency: confirmed by whether PT is corrected within 24–48 hours after vitamin K administration. Liver disease: accompanied by reductions in several liver-synthesized factors, so APTT is also often prolonged. Congenital FVII deficiency: confirmed by FVII:C single-factor assay after warfarin and vitamin K deficiency have been excluded. Congenital FX, FV, FII (prothrombin) deficiency: these prolong both PT and APTT, so they are excluded in isolated PT prolongation. In this differentiation process, systematically excluding the effects of warfarin and vitamin K first is an efficient approach that reduces the cost of unnecessary factor measurements.

FVII:C single-factor assay and severity determination

To confirm that FVII deficiency is the cause of PT prolongation, an FVII:C single-factor assay (one-stage APTT-based or PT-based method) is performed. FVII:C is usually quantified by a one-stage method using FVII-deficient substrate plasma, and severity is classified according to the result: FVII:C <1 IU/dL (severe), 1–10 IU/dL (moderate), 10–50 IU/dL (mild), 50–70 IU/dL (heterozygous carrier range). It is important to confirm that vitamin K status is normal at the time of testing, because a low FVII:C measured during vitamin K deficiency may be an underestimate of congenital deficiency. A mixing test (patient plasma + normal plasma 1:1) is performed to check whether PT is corrected; if corrected, factor deficiency is likely, and if not, an inhibitor (rare) or lupus anticoagulant is suspected. By comparison with FVII antigen (FVII:Ag) measurement, type I (CRM−, reduced FVII:Ag) and type II (CRM+, normal or increased FVII:Ag, with only function reduced) can be distinguished.

Findings on thrombin generation assays and whole blood viscoelastic testing

On the thrombin generation assay (TGA), the effect of FVII deficiency differs according to the initiation conditions. Under TF-triggered (low-concentration TF) conditions, the TF-FVIIa pathway is the main initiation pathway, so FVII deficiency shows prolonged lag time of thrombin generation and reduced endogenous thrombin potential (ETP). In contrast, when high-concentration TF or FVII-independent activation conditions are used, the effect of FVII deficiency may be relatively reduced. On whole blood viscoelastic testing (TEG/ROTEM), FVII deficiency may show prolonged clot formation time (CFT) on EXTEM (extrinsic pathway activation), but it is difficult to quantitatively assess the degree of FVII deficiency with this test alone. When using TEG/ROTEM to manage intraoperative bleeding, care should be taken not to confuse CFT prolongation due to FVII deficiency with other causes (low fibrinogen, thrombocytopenia, etc.).


8. Screening

Detection of isolated PT prolongation before surgery

The most common clinical route for detecting FVII deficiency (hypoproconvertinemia) is the finding of isolated PT prolongation on routine preoperative coagulation screening. When only PT is prolonged with normal APTT, TT, and platelets, the first thing to check is whether the patient is taking a vitamin K antagonist (warfarin, etc.) or a direct oral anticoagulant. Once anticoagulant use is excluded, the possibility of vitamin K deficiency is reviewed, and if necessary vitamin K is given to check whether PT is corrected. When these two acquired causes are excluded, single-factor assays are performed to evaluate the possibility of isolated FVII deficiency (hypoproconvertinemia) or deficiency of other extrinsic pathway factors (FX, FV, FII). Because among the extrinsic pathway factors only FVII has no effect on APTT, the pattern of isolated PT prolongation + normal APTT strongly suggests FVII deficiency.

Assessment of vitamin K status and differentiation from vitamin K deficiency

When isolated PT prolongation is found, differentiating congenital FVII deficiency from vitamin K deficiency is practically the most important step. Risk factors for vitamin K deficiency are as follows: inadequate nutritional intake (especially in the elderly and with postoperative fasting), broad-spectrum antibiotic use (reduction of vitamin K-synthesizing gut bacteria), malabsorption disorders (Crohn disease, short bowel syndrome, biliary obstruction, cystic fibrosis), and total parenteral nutrition (TPN) combined with broad-spectrum antibiotics. PT is remeasured 24–48 hours after intravenous injection of vitamin K 5–10 mg to check for correction. If corrected, it is vitamin K deficiency or vitamin K-dependent coagulation factor deficiency (VKCFD); if not corrected, congenital FVII deficiency is likely. Because vitamin K deficiency can also coexist with congenital FVII deficiency, overlap of the two causes should be considered if PT is only partially corrected after vitamin K administration.

Family history investigation and family testing

When congenital FVII deficiency is suspected, family history investigation is an important screening tool. It is checked whether any family member has an unexplained bleeding tendency, has had a PT abnormality found before surgery, or has already been diagnosed with FVII deficiency. Because inheritance is autosomal recessive, siblings may have the deficiency if the parents are heterozygous carriers. For family testing, FVII:C measurement is recommended to parents and siblings, and the results are used for genetic counseling and preoperative management planning. If FVII:C testing at birth is planned for the newborn of a pregnant woman with a family history, severe deficiency can be detected before bleeding occurs and treatment can be started immediately.

Screening in women planning pregnancy and in newborns

In the pregnancy management of women with FVII deficiency or female heterozygous carriers of FVII deficiency, the baseline FVII:C level is checked before pregnancy and changes in FVII:C are followed during pregnancy (FVII rises physiologically in normal pregnancy, so levels may become relatively higher even when deficiency is present). FVII:C is measured before delivery, and if FVII:C <10–20 IU/dL, rFVIIa or plasma-derived FVII concentrate is prepared for delivery. When there is a family history of FVII deficiency, FVII:C and PT are measured in cord blood immediately after birth to determine whether the newborn is deficient. If the newborn has prolonged PT, both vitamin K deficiency (hemorrhagic disease of the newborn) and congenital FVII deficiency are considered and differentiated by the response to vitamin K administration.


9. Diagnosis

Diagnostic algorithm: from PT prolongation to F7 gene analysis

The stepwise approach to definitive diagnosis of FVII deficiency (hypoproconvertinemia) is as follows. Step 1: confirm isolated PT prolongation (normal APTT, normal TT, normal platelets). Step 2: check for and exclude use of warfarin, vitamin K antagonists, or NOACs. Step 3: differentiate vitamin K deficiency by remeasuring PT 24–48 hours after vitamin K administration (5–10 mg IV or oral). Step 4: if PT prolongation is not corrected by vitamin K, measure FVII:C, FX:C, FV:C, and FII:C to identify the deficient factor (isolated FVII deficiency is confirmed if only FVII:C is reduced and the rest are normal). Step 5: exclude an inhibitor with a mixing test. Step 6: distinguish type I (CRM−) and type II (CRM+) by FVII:A antigen measurement. Step 7: for definitive diagnosis and genetic counseling, perform F7 gene analysis (Sanger sequencing or NGS panel) to identify the pathogenic variant.

Reagent dependence of FVII:C measurement

Caution is needed with FVII:C measurement because results can differ depending on the type of reagent used. In PT-based FVII:C measurement, reactivity with certain CRM+ variants (e.g., FVII Val(294)Asp, Cys(310)Phe) may differ depending on the type of TF in the PT reagent (human recombinant TF, bovine brain TF, rabbit brain TF, etc.). Some variant FVII proteins do not bind well to TF from certain species, so FVII:C may be measured lower than it actually is when reagents using that TF are used. This phenomenon is known as reagent discrepancy, and measuring FVII:C with several different reagents or confirming with a chromogenic assay allows more accurate determination of the actual residual activity of the variant FVII. Recognizing this reagent-dependent measurement variation in clinical interpretation prevents overdiagnosis or underdiagnosis of FVII deficiency.

F7 gene analysis and variant interpretation

F7 gene analysis is performed for definitive diagnosis and genetic counseling when FVII:C is clinically markedly reduced. All 9 exons and exon-intron boundaries of the F7 gene are analyzed by Sanger sequencing, or multiple coagulation factor genes are analyzed simultaneously with an NGS-based rare bleeding disorder panel. Identified variants are classified for pathogenicity according to ACMG/AMP criteria. In particular, for CRM+ variants (low FVII:C but normal or increased FVII:Ag), pathogenicity is assessed by integrating the structural location of the variant and known clinical phenotype data. When homozygous or compound heterozygous variants are identified in the F7 gene, FVII deficiency is confirmed, and this is used for severity prediction and treatment planning. When only a heterozygous variant is found, Copy Number Variation (CNV) analysis may additionally be considered to check for a missed variant on the other allele.

Severity classification and treatment planning

Based on FVII:C measurement results, the severity of the deficiency is classified and a corresponding management plan is established. Severe (<1 IU/dL): long-term prophylaxis strongly recommended; prevention of intracranial hemorrhage is the top priority; plan for regular (2–3 times a week or continuous) rFVIIa administration. Moderate (1–10 IU/dL): indications for prophylaxis individualized according to bleeding history and clinical situation; an FVII replacement plan must be established before surgery. Mild (>10 IU/dL): prophylaxis mostly unnecessary; hematology consultation before high-risk surgery; tranexamic acid alone may be sufficient for minor procedures. This severity classification must be interpreted clinically by integrating the patient's past bleeding history (including the ISTH-BAT score) together with the FVII:C value, and when the value and the clinical course are discordant, the clinical course is given more weight.


10. Treatment

Recombinant activated FVIIa (rFVIIa, NovoSeven®)

The most important treatment option for FVII deficiency is recombinant activated FVII (rFVIIa, eptacog alfa activated, brand name NovoSeven®, Novo Nordisk). rFVIIa is a recombinant form of human FVIIa expressed in baby hamster kidney (BHK) cells and then purified and inactivation-treated. Because it is already in the activated FVIIa form, immediately after administration it can form a complex with endogenous TF and initiate the extrinsic pathway at once. The definitive indication of rFVIIa in FVII deficiency is approved by the FDA and EMA, and it is used for both treatment of acute bleeding and preoperative prophylaxis. The dose ranges from 15–30 μg/kg (intravenous) depending on bleeding severity and type of surgery, and because the half-life is short at about 2.7 hours, repeated dosing every 2–6 hours is needed during the period requiring hemostasis during and immediately after surgery. Because rFVIIa carries a potential risk of thrombosis (overactivation of the TF pathway), it should be used with caution in patients with thrombotic risk factors.

Plasma-derived FVII concentrate and FFP

Plasma-derived FVII concentrate (e.g., Factor VII concentrate, available in some countries) is a product in which FVII is purified from human plasma and virus-inactivated. The advantage of this product is that its half-life of about 3–6 hours is somewhat longer than that of rFVIIa, allowing longer dosing intervals. However, the availability of specialized FVII concentrates differs by country, and in Korea access to commercial FVII-only concentrates may be limited. Fresh frozen plasma (FFP) contains all coagulation factors including FVII and can therefore be used to treat FVII deficiency, but it requires large volumes, carrying a risk of volume overload, and also a risk of viral transmission. The FVII content of FFP is about 1 IU/mL, and a considerable volume (10–15 mL/kg) is needed to raise FVII:C significantly. Therefore, FFP is used as an alternative in emergencies when access to specialized products is difficult.

Long-term prophylaxis and treatment goals

Long-term prophylaxis is considered in patients with severe FVII deficiency (FVII:C <1 IU/dL) or who have experienced recurrent bleeding. The most important purpose of prophylaxis is prevention of intracranial hemorrhage, which is particularly emphasized in children. The target FVII:C trough level for prophylaxis is generally set at 15–25 IU/dL or above. Long-term prophylaxis with rFVIIa requires dosing 2–3 times a week or every other day because of its short half-life, which demands high adherence and intravenous injection skills from patients and caregivers. Home therapy programs increase the feasibility of long-term prophylaxis, and children are trained to join such programs as early as possible. The introduction of an rFVIIa formulation that can be given subcutaneously (Alhemo®, subcutaneous rFVIIa formulation, Novo Nordisk, approved in some countries) is improving convenience of administration.

Vitamin K and other supportive treatments

Vitamin K administration plays a limited role in congenital FVII deficiency. When the vitamin K-dependent gamma-carboxylation function itself is normal but the FVII protein is not produced or is nonfunctional due to an FVII gene variant, FVII:C does not rise meaningfully no matter how much vitamin K is given. However, in some CRM+ variant cases in which carboxylation of the residual FVII protein is incomplete, FVII:C may rise slightly with high-dose vitamin K. Tranexamic acid, through its antifibrinolytic effect, can be used as adjunctive treatment in mild FVII deficiency and is particularly useful for mucosal bleeding (nosebleeds, gum bleeding, menorrhagia). Topical application of tranexamic acid (mouthwash) is also effective for oral mucosal bleeding. DDAVP (desmopressin) has no significant effect in FVII deficiency and is not recommended.


11. Prognosis

Differences in prognosis by severity

The prognosis of FVII deficiency (hypoproconvertinemia) differs greatly depending on the severity of the deficiency and access to appropriate treatment. In mild deficiency (FVII:C >10 IU/dL), a mostly normal life expectancy and quality of life are expected, and with appropriate preparation for high-risk surgery or childbirth, patients can live without complications. In moderate deficiency (FVII:C 1–10 IU/dL), prevention is possible with appropriate treatment in situations of hemostatic stress such as surgery and delivery, but serious bleeding complications can occur if access to treatment is delayed. In severe deficiency (FVII:C <1 IU/dL), the risk of intracranial hemorrhage is high and the prognosis is serious without prophylactic treatment, but a normal life is possible with early diagnosis and regular prophylaxis. In particular, once intracranial hemorrhage has occurred, permanent neurological damage may remain, so prevention is most important.

Discordance between FVII:C and bleeding prognosis

The disproportionate relationship between FVII:C and clinical bleeding severity is a key characteristic that makes prognostic prediction difficult. Because bleeding tendency can differ greatly even at the same FVII:C, the need for and intensity of prophylaxis cannot be decided by the FVII:C value alone. Clinically, patients with severe FVII:C (<1 IU/dL) who lived their whole lives without serious bleeding have been reported, and conversely there are cases of intracranial hemorrhage in patients with FVII:C of 5–10 IU/dL. Because of this unpredictability, individual management plans for FVII deficiency patients must be decided by integrating the FVII:C value, past bleeding history (ISTH-BAT score), type of variant (CRM+ vs. CRM−, variant location), family history, etc. Even in patients on prophylaxis, the treatment regimen (dose, frequency) is reassessed when a new bleeding event occurs.

Joint complications and quality of life

When recurrent joint bleeding (hemarthrosis) occurs in patients with severe FVII deficiency, hemophilic arthropathy similar to that in severe hemophilia A and B may progress. When cartilage destruction, joint stiffness, and chronic pain develop, rehabilitation and orthopedic management are needed. There are reports that the frequency of joint bleeding in severe FVII deficiency is lower than in hemophilia A and B, but joint complications can occur when left without appropriate prophylaxis for a long time. When prophylaxis is given, progression of arthropathy can be effectively prevented. In terms of quality of life, the burden of long-term intravenous prophylaxis (frequent hospital visits or home self-administration required) can be considerable for patients, so the development of subcutaneous formulations or products with longer half-lives is clinically important.

Thrombotic risk associated with rFVIIa

A rare but clinically important complication of FVII deficiency treatment with rFVIIa is thromboembolism. When rFVIIa overactivates the TF pathway, venous or arterial thrombotic events can occur, especially in patients with overlapping thrombotic risk factors (advanced age, atherosclerosis, obesity, prolonged immobilization, postoperative state). In clinical trials, thrombotic complications have been reported when rFVIIa was used for other indications (off-label indications other than FVII deficiency). At the standard treatment dose for FVII deficiency (15–30 μg/kg), the thrombotic risk is relatively low, but caution is needed with high-dose or repeated administration. Therefore, during rFVIIa treatment, changes in clinical symptoms (leg pain and swelling, chest pain, dyspnea, etc.) are carefully observed, and if thrombosis is suspected, the need for anticoagulation is assessed.


12. Prevention

Long-term prophylaxis in severe deficiency

In patients with severe FVII deficiency (FVII:C <1 IU/dL) or a history of intracranial hemorrhage, long-term prophylaxis is the key means of preventing recurrent intracranial hemorrhage and other serious spontaneous bleeding. rFVIIa (NovoSeven®) is given as an intravenous injection of 15–30 μg/kg 2–3 times a week or every other day, maintaining a target FVII:C trough level of 15–25 IU/dL or above. The effectiveness of prophylaxis is assessed by regular monitoring of FVII:C trough levels and recording of bleeding events. In children, starting prophylaxis as early as possible is important for preventing intracranial hemorrhage and maintaining normal development. Home therapy training that enables patients or caregivers to administer the drug themselves reduces the frequency of hospital visits and improves the quality of daily life.

Preoperative prophylaxis planning

Whenever an FVII deficiency patient undergoes any surgery or invasive procedure, an FVII replacement plan is established in advance in consultation with a hematologist. Target FVII:C levels are set differently according to the extent and site of surgery: minor surgery (tooth extraction, minor skin surgery): FVII:C 15–25 IU/dL or above; intermediate surgery: 25–50 IU/dL; major surgery (intracranial surgery, intra-abdominal surgery, joint replacement): 50–100 IU/dL. rFVIIa is given immediately before surgery, and considering the short half-life of FVII, a redosing plan every 2–6 hours for 24–48 hours after surgery is established. PT is monitored during surgery to indirectly confirm the effect of FVII replacement, and patients are educated about symptoms of delayed postoperative bleeding. In emergencies where surgery is imminent, FFP can be used as an urgent alternative, but if specialized products are accessible, rFVIIa or plasma-derived FVII concentrate is preferred over FFP.

Prevention of vitamin K deficiency and dietary management

When vitamin K deficiency is superimposed in patients with congenital FVII deficiency, FVII:C falls further and the bleeding risk increases. Therefore, maintaining adequate vitamin K intake (vitamin K-rich foods: green leafy vegetables, broccoli, spinach, etc.) is important. When disorders of vitamin K absorption (liver disease, malabsorption syndromes) are present, oral vitamin K supplementation is considered. During long-term use of broad-spectrum antibiotics, vitamin K-synthesizing gut bacteria decrease and vitamin K status may worsen, so prophylactic oral vitamin K supplementation during this period is considered. Because vitamin K antagonists (warfarin) inhibit vitamin K-dependent factors including FVII, warfarin is avoided in FVII deficiency patients unless there is an indication for anticoagulation.

Genetic counseling and family management

Genetic counseling is provided to families of FVII deficiency patients. The content includes the autosomal recessive mode of inheritance, the probability (25%) of a child with complete deficiency being born to heterozygous carrier parents, and the possibility of family carrier testing through identification of the F7 gene variant. FVII deficiency patients or heterozygous carrier couples planning pregnancy are informed about the possibility of prenatal genetic testing (chorionic villus sampling or amniocentesis). For newborns confirmed to have FVII deficiency, immediate clinical evaluation and a bleeding prevention plan are established, and the whole family is advised to carry an emergency medical information card or bracelet. The FVII deficiency diagnosis, severity, and treatment plan are clearly recorded in the medical record so that other clinicians can promptly provide appropriate treatment in emergencies.


13. References

  1. Alexander B, Goldstein R, Landwehr G, Cook CD. Congenital SPCA deficiency: a hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions. J Clin Invest. 1951;30(6):596-608.
  2. Owren PA. The coagulation of blood: investigations on a new clotting factor. Acta Med Scand Suppl. 1947;194:1-327.
  3. Mariani G, Bernardi F. Factor VII Deficiency. Semin Thromb Hemost. 2009;35(4):400-406.
  4. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10(4):615-621.
  5. Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci. 1998;19(2):163-176.
  6. Bernardi F, Dolce A, Pinotti M, et al. Dominant missense mutations in the role of factor VII in hemostasis: from case reports to a classification scheme. J Thromb Haemost. 2009;7(3):467-475.
  7. Giansily-Blaizot M, Schved JF. Potential predictors of bleeding risk in inherited factor VII deficiency: can biological tests and molecular data be useful? Thromb Haemost. 2005;94(2):287-291.
  8. Siboni SM, Tamaro C, Linari S, et al. Rare bleeding disorders management at transition from paediatric to adult care: an Italian multicentre study. Haemophilia. 2022;28(5):814-822.
  9. Napolitano M, Kessler CM, Rangarajan S, et al. Recombinant activated factor VII for acute bleeding in congenital factor VII deficiency: a prospective evaluation. Haemophilia. 2013;19(6):872-878.
  10. de Paula EV, Hsi CP, Trowbridge M, et al. Management of rare congenital coagulation factor deficiencies during pregnancy. Haemophilia. 2016;22(3):e163-e171.
  11. World Federation of Hemophilia. Guidelines for the Management of Hemophilia, 3rd ed. Montreal: WFH; 2020.
  12. Bolton-Maggs PHB, Perry DJ, Chalmers EA, et al. The rare coagulation disorders: review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia. 2004;10(5):593-628.